trending Market Intelligence /marketintelligence/en/news-insights/trending/qGF6hpamslNkeglE4-0jAQ2 content esgSubNav
In This List

Sumitomo fails to reach agreement to acquire Cynata Therapeutics

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Sumitomo fails to reach agreement to acquire Cynata Therapeutics

Sumitomo Dainippon Pharma Co. Ltd. failed to reach an agreement on terms to acquire stem cell technology company Cynata Therapeutics Ltd.

The parties have withdrawn from the acquisition discussions after failing to arrive at a deal.

The Osaka, Japan-based drugmaker previously offered to acquire Australia's Cynata for A$2 per share in cash under a scheme of agreement.

The offer, made in July, valued the stem cell and regenerative medicines company at about A$203.8 million.

Sumitomo manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics and other products.

Cynata, which offers a mesenchymal stem cell technology, is developing its lead product candidate CYP-001 as a treatment for graft versus host disease.